Friday, June 30, 2017

Gadolinium Build Up


Gadolinium Builds Even in Normal Brains

Underlying brain pathology may not be culprit in buildup after contrast MRI

Action Points

Gadolinium from imaging contrast agents sticks to neural tissues even in patients who don't have intracranial abnormalities, according to a small, single-center, retrospective study.
In a postmortem study comparing tissues from the brains of five patients who had several magnetic resonance imaging (MRI) scans using gadolinium with 10 patients who had MRIs without contrast, elemental gadolinium was detected in four neuroanatomic regions of all five patients, with concentrations ranging from 0.1 to 19.4 mcg per gram of tissue, Robert McDonald, MD, PhD, of the Mayo Clinic in Rochester, Minn., and colleagues reported online in Radiology. No gadolinium was detected in the brains of controls.
"Our results suggest that current thinking with regard to the permeability of the blood brain barrier is greatly oversimplified, as gadolinium appears to accumulate even among patients with normal brain tissue and no history of intracranial pathology," McDonald said in a statement. "It will take additional research to understand how and why this deposition is occurring."
The authors were quick to note, however, that they did not find any histologic changes that suggested toxicity. However, further investigation is needed, they said, "in light of the cytotoxic and genotoxic potential of free lanthanide rare earth metals."
Just last month, the FDA similarly concluded that there are no adverse health effects from gadolinium retained in the brain after contrast MRI, so restricting use of the agent is not warranted. But the agency said it would have a public meeting on the issue in the future.
McDonald and colleagues said their study bolsters previous research in patients who have intracranial abnormalities -- underlying brain pathology such as a tumor or infection that was thought to be the culprit behind gadolinium buildup.
But in the McDonald et al study, the researchers assessed patients who had contrast MRI mainly for gut imaging, to test the hypothesis that gadolinium accumulation would occur in those with normal brains, too, as some recent evidence has suggested.
The team studied postmortem neuronal tissue samples from five patients who had four to 18 gadolinium-enhancing MRI scans between 2005 and 2015 and 10 patients who had MRI scans without the agent (none had neurologic symptoms, and imaging was mainly for intraabdominal or intrapelvic disease). The tissue was studied with electron microscopy, mass spectroscopy, and x-ray spectroscopy. The median age at the time of death was 68 in the contrast MRI group and 79 in the control group.
Overall, McDonald and colleagues found dose-dependent gadolinium deposits in four neuroanatomical brain regions in those who had contrast MRI, with concentrations ranging from 0.1 to 19.4 mcg of gadolinium per gram of tissue. These were highest in the globus pallidus and in the dentate nucleus.
None of the patients in the control group had detectable levels of elemental gadolinium.
Both the globus pallidus and the dentate nucleus are prone to mineralization and hemorrhage, which "may suggest that parts of the brain may have a less robust barrier and may be more susceptible to this deposition," McDonald explained. In addition, gadolinium is similar to calcium in size and charge, so the body may mistake it for the endogenous metal, which is often taken up in areas of brain as patients age.
Regarding study limitations, the researchers noted the small number of patients, so it was not possible to analyze the data with multivariate methods. In addition, the findings are not applicable to more stable macrocyclic gadolinium chelates, since gadodiamide was the only contrast agent used.
Implications for MS Patients?
Patients with multiple sclerosis (MS) have long been raising questions about frequent contrast-enhancing brain scans, but MS experts contacted by MedPage Today said the new results don't have any impact on current practice -- notably because the data are from people without underlying brain pathology.
For example, John Corboy, MD, of the University of Colorado in Denver, noted that clinicians try to limit the use of gadolinium because of a lack of complete understanding of the potential risks, the cost, and the side effects, since some patients get a distinct taste in their mouth and others have a true allergy.
"In a stable [MS] patient, it does not add that much info, especially in older stable patients," Corboy said of gadolinium-enhancing scans. "So, we use them for diagnosis, for clinical changes, and to rule out other pathology as needed -- for example, a brain tumor. Otherwise, we try to avoid it. We can also use different dyes that have lesser risks of being taken up in brain or other tissues."
Fred Lublin, MD, director of the Center for Multiple Sclerosis at Mount Sinai Medical Center in New York City, agreed that the data will not change practice: "While there is currently no evidence of any harmful effects of retained gadolinium, since this issue has arisen, we now determine on each ordered scan whether gadolinium is needed," he said

Wednesday, June 28, 2017

Senator Casey Responds

I sent the letter linked here TO SENATORS CASEY & TOOMEY. Senator Casey responded June 27 with the following:

Dear Mr. Austin:

In the past you have contacted my office regarding efforts to repeal the Patient Protection and Affordable Care Act (ACA). I write today to update you on recent developments on this topic.

As you may be aware, the Senate majority plans to bring their health care scheme to a vote after the Senate returns from the July 4 recess. The proposal of the Senate majority was developed without hearings, with no amendments from the minority and without adequate opportunity for public input. The proposal would have significant damaging effects and is being advanced despite polls showing broad public opposition. If successful, it will decimate the health insurance of millions of Americans and shred important protections that individuals have come to count on, in Pennsylvania and throughout our Nation.

The majority in Congress is attempting to advance this legislation through an expedited process known as “budget reconciliation.” This process allows the Senate majority to advance its proposal with special procedures which limit debate on the proposal and allow the legislation to advance without the support of a single member of the minority.

The House of Representatives passed their health care plan, the American Healthcare Act, on May 4, 2017. The legislation, which President Trump has endorsed, is inconsistent with a number of promises that he has made, first as a candidate and then as President. For example, the legislation allows health insurance companies to discriminate against individuals with pre-existing conditions, cuts over $800 billion from the Medicaid Program, and undermines Medicare’s financing, which increases the chance that others may seek Medicare cuts in the future to forestall insolvency. According to the Congressional Budget Office, the legislation would also cause 23 million people to lose health insurance and would raise costs for millions more.

Following House passage, the American Healthcare Act came to the Senate, where the majority opted to develop its own plan. A group of thirteen Senators spent two months meeting in secret to develop this new scheme, the Better Care Reconciliation Act. The minority was not invited to be a part of this process. This is in stark contrast to the process used to formulate the Affordable Care Act. In 2009, the ACA passed the Senate after a year-long open process that included a total of 44 bipartisan hearings, roundtables and summits in the Senate Committees of jurisdiction; the Committee on Health, Education, Labor, and Pensions and the Committee on Finance. Senate consideration of the ACA also included over a month of Committee markups that led to the consideration of 435 amendments offered by both the majority and the minority, and a full debate on the Senate floor that lasted over 25 consecutive days.

The Senate majority released the Better Care Reconciliation Act to the public on June 22. The proposal will allow the states to strip key consumer protections from the ACA; increase out-of-pocket costs; take away coverage for substance abuse treatment, which is vital in combatting the opioid epidemic; and drastically increase costs for seniors by implementing an age tax on their health care. Further, this scheme will decimate Medicaid, hurting children, individuals with disabilities and hospitals throughout our state. Although the Senate majority claimed they would completely rewrite the House legislation, in reality, the Better Care Reconciliation Act closely resembles the House proposal. Like the House bill, it cuts health care for millions of middle class Americans and their families in order to provide tax cuts to wealthy Americans. After years of making significant strides in improving our health care system, this is not the direction we should take.

It appears that the majority in the Senate will seek final passage of its legislation after the July 4 recess. I remain hopeful that members of the majority will listen to their constituents and carefully consider how this plan will negatively impact the communities they represent. I hope that instead of considering this proposal, the majority might get serious, end their focus on repealing the ACA and work in a bipartisan way to keep what is working with the health care system and fix what is not.

The upcoming vote may be a major turning point for the health of our Nation. Patients, advocates, health care providers and the general public should have adequate opportunity to shape any plan that emerges from the Senate. The current process has not allowed for that. Further, any changes to our health care system must maintain or expand coverage, quality and care. The Senate majority’s scheme does not meet that standard, and I will continue to fight it with everything I have.

Sincerely,
Bob Casey
United States Senator

Tuesday, June 27, 2017

Letter to Senators Robert Casey & Patrick Toomey

Vote No on the Better Care Reconciliation Act Protect People with MS

Dear (Senator Casey & Senator Toomey),

As a person impacted by multiple sclerosis and your constituent, I urge you to VOTE NO on the Better Care Reconciliation Act.

The Senate's Better Care Reconciliation Act of 2017 will reduce access to coverage, make coverage and care less affordable, and fails to provide and protect comprehensive insurance. 

- By eliminating the Medicaid expansion enacted under the Affordable Care Act, which gave states additional funding to offer insurance coverage to low-income people up to 133% of the poverty line.
- By jeopardizing all Medicaid services by capping all federal Medicaid funding starting in year 2025, significantly reducing state funds and forcing every state to make hard choices like eliminating health and supportive services, cutting beneficiaries out of the program, and more. 
- Allowing states to opt out of vital patient protections that are especially important for people with high-cost medical conditions. These protections include the current caps on out-of-pocket costs and bans on insurers' use of lifetime and annual limits of coverage.
- Allowing states to opt out of the current requirements that insurers must cover 10 'Essential Health Benefits.'

Please vote NO on the Better Care Reconciliation Act when the U.S. Senate considers the bill.


Sincerely,
Frank Austin

Better Care?

CBO Summary of Senate Health Care Bill, Summary, page 7 

Rural America Take Note...Frank

In the agencies’ assessment, a small fraction of the population resides in areas in which—because of this legislation, at least for some of the years after 2019—no insurers would participate in the nongroup market or insurance would be offered only with very high premiums. Some sparsely populated areas might have no nongroup insurance offered because the reductions in subsidies would lead fewer people to decide to purchase insurance—and markets with few purchasers are less profitable for insurers. Insurance covering certain services would become more expensive—in some cases, extremely expensive—in some areas because the scope of the EHBs would be narrowed through waivers affecting close to half the population, CBO and JCT expect. In addition, the agencies anticipate that all insurance in the nongroup market would become very expensive for at least a short period of time for a small fraction of the population residing in areas in which states’ implementation of waivers with major changes caused market disruption.

Senator Bob Casey Quote


"The GOP plan is particularly obscene when you realize every one of those senators has health care that will be unaffected by this." Senator Robert Casey 

Monday, June 26, 2017

Average Family Premium per Enrolled Employee

http://www.kff.org/other/state-indicator/family-coverage/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D

Average Family Premium per Enrolled Employee For Employer-Based Health Insurance

Employee Contribution    Employer Contribution  Total Cost

          $4,710                                      $12,612           $17,322

The Better Care Reconciliation Act

Retter? OK, but for who?
   Frank

https://www.nationalmssociety.org/About-the-Society/News/HealthcareBill-6-22

MS Society Disappointed with Senate Healthcare Bill

June 22, 2017
The National Multiple Sclerosis Society today expresses disappointment with the Senate Republican’s Healthcare bill. Despite hundreds of meetings with and thousands of letters and calls to Congress by MS activists explaining the care and coverage people living with the disease need to live their best live, the Senate produced legislation behind closed doors that does not meet these needs.
 
“The National MS Society believes the Senate bill is ill-conceived and should be rejected,” says Bari Talente, Executive Vice President of Advocacy. “While we await specifics about expected coverage losses and fiscal impact from the Congressional Budget Office, the Society encourages Senators to reject the Better Care Reconciliation Act of 2017 as it does not improve access to coverage and care for people living with MS. Healthcare is too important for a bill to be developed by a handful of people in a back room that doesn’t account for the real needs of people who rely on their health coverage.”
 
People like Marques Jones of Richmond, VA who was diagnosed with MS eight years ago.
 
“If the Senate votes to repeal protections gained with the ACA, all the hard work I’ve done to fight this terrible illness, start my own business, and keep living my life to the fullest for myself and, most of all, my family will be lost.  I’ll be at the mercy of the health insurance companies, my hold on the American dream will be broken, and my ability to strive for a better life…be thrown into chaos and uncertainty,” said Jones. Read more about Jones in a recent Momentum magazine article.
 

“While some of the Senate’s proposed policy changes are being touted as providing people with choice and flexibility, people do not choose to be diagnosed with a chronic, expensive condition such as MS,” explains Talente. “An MS diagnosis, other diagnoses or life-altering incidents like car accidents can happen to anyone—at any time. Access is meaningless—and will ultimately cost our country more—unless it is affordable and covers the comprehensive care that people need.” Read more about the impact of the Better Care Reconciliation Act.